



4 June 2018

ASX Announcement

Expiry of Unlisted Options

Race Oncology Limited (ASX: RAC) hereby advises that the Company has the following options on issue as at 4 June 2018:

Expiry Date	Exercise Price	Options
1 July 2018	\$0.25	10,000,000
30 September 2018	\$0.30	9,723,750
22 November 2019	\$0.49	1,000,000
22 November 2019	\$0.65	1,000,000
1 July 2021	\$0.25	9,000,000
1 August 2021	\$0.256	135,000
1 April 2022	\$0.25	1,500,000
8 May 2022	\$0.25	100,000

This follows the accelerated expiry of 1,000,000 unlisted \$0.49 options expiring 22 November 2019 and 1,000,000 unlisted \$0.65 options expiring 22 November 2019 following the resignation of a Director in April 2018.

Ends

About Bisantrene

Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers, but has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race owns two patents on the drug, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s before it was lost in a series of big pharma mergers.

Media contact:

Heidi Cuthbert
0411 272 366
E: heidi.cuthbert@multiplier.com.au